These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 9447899)
21. Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery. Kanellakopoulou K; Giamarellou H; Papadothomakos P; Tsipras H; Chloroyiannis J; Theakou R; Sfikakis P Eur J Clin Microbiol Infect Dis; 1993 Jun; 12(6):449-53. PubMed ID: 8359165 [TBL] [Abstract][Full Text] [Related]
22. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Zanetti G; Bally F; Greub G; Garbino J; Kinge T; Lew D; Romand JA; Bille J; Aymon D; Stratchounski L; Krawczyk L; Rubinstein E; Schaller MD; Chiolero R; Glauser MP; Cometta A; Antimicrob Agents Chemother; 2003 Nov; 47(11):3442-7. PubMed ID: 14576100 [TBL] [Abstract][Full Text] [Related]
23. Empiric carbapenem monotherapy in pediatric bone marrow transplant recipients. Nelson WK; Rayback PA; Quinones R; Giller RH Ann Pharmacother; 2002 Sep; 36(9):1360-5. PubMed ID: 12196052 [TBL] [Abstract][Full Text] [Related]
24. Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. Romanelli G; Cravarezza P; Pozzi A; Franchino L; Ravizzola G; Zulli R; Donati P; Prometti P; Grassi V J Chemother; 2002 Dec; 14(6):609-17. PubMed ID: 12583553 [TBL] [Abstract][Full Text] [Related]
25. Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections. Naber KG; Savov O; Salmen HC Int J Antimicrob Agents; 2002 Feb; 19(2):95-103. PubMed ID: 11850161 [TBL] [Abstract][Full Text] [Related]
26. Changing role of carbapenems in the treatment of lower respiratory tract infections. Lode H; Hamacher J; Eller J; Schaberg T Scand J Infect Dis Suppl; 1995; 96():17-23. PubMed ID: 7652498 [TBL] [Abstract][Full Text] [Related]
27. Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial. Nakane T; Tamura K; Hino M; Tamaki T; Yoshida I; Fukushima T; Tatsumi Y; Nakagawa Y; Hatanaka K; Takahashi T; Akiyama N; Tanimoto M; Ohyashiki K; Urabe A; Masaoka T; Kanamaru A; J Infect Chemother; 2015 Jan; 21(1):16-22. PubMed ID: 25239059 [TBL] [Abstract][Full Text] [Related]
28. A multicenter, randomized controlled clinical study on biapenem and imipenem/cilastatin injection in the treatment of respiratory and urinary tract infections. Jia B; Lu P; Huang W; Li C; Huang A; Zhou X; Zhang W; Wu G; Zhang G Chemotherapy; 2010; 56(4):285-90. PubMed ID: 20714145 [TBL] [Abstract][Full Text] [Related]
32. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin. Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636 [TBL] [Abstract][Full Text] [Related]
33. Comparison of imipenem/cilastatin with the combination of aztreonam and clindamycin in the treatment of intra-abdominal infections. de Groot HG; Hustinx PA; Lampe AS; Oosterwijk WM J Antimicrob Chemother; 1993 Sep; 32(3):491-500. PubMed ID: 8262872 [TBL] [Abstract][Full Text] [Related]
34. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Hornik CP; Herring AH; Benjamin DK; Capparelli EV; Kearns GL; van den Anker J; Cohen-Wolkowiez M; Clark RH; Smith PB; Pediatr Infect Dis J; 2013 Jul; 32(7):748-53. PubMed ID: 23838776 [TBL] [Abstract][Full Text] [Related]
35. Carbapenems: monotherapy in intra-abdominal sepsis. Wilson SE Scand J Infect Dis Suppl; 1995; 96():28-33. PubMed ID: 7652500 [TBL] [Abstract][Full Text] [Related]
36. [A randomized, controlled clinical trial of meropenem and imipenem/cilastatin in the treatment of acute bacterial infections]. Hou F; Wu G; Zheng B Zhonghua Nei Ke Za Zhi; 2001 Sep; 40(9):589-93. PubMed ID: 11758237 [TBL] [Abstract][Full Text] [Related]
37. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group. Fink MP; Snydman DR; Niederman MS; Leeper KV; Johnson RH; Heard SO; Wunderink RG; Caldwell JW; Schentag JJ; Siami GA Antimicrob Agents Chemother; 1994 Mar; 38(3):547-57. PubMed ID: 8203853 [TBL] [Abstract][Full Text] [Related]
38. Carbapenems in serious infections: a risk-benefit assessment. Norrby SR Drug Saf; 2000 Mar; 22(3):191-4. PubMed ID: 10738843 [TBL] [Abstract][Full Text] [Related]
39. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889 [TBL] [Abstract][Full Text] [Related]
40. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group. Eklund AE; Nord CE J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]